TCIM
ACET icon

TIAA CREF Investment Management’s Adicet Bio ACET Stock Holding History

TIAA CREF Investment Management’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-92
Closed -$94K – 3055
2018
Q2 		$94K Sell
92
-42
-31% -$45.2K ﹤0.01% 3069
2018
Q1 		$143K Buy
+134
New +$246K ﹤0.01% 2999

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SCM
Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DAM
Deltec Asset Management New York $545M AUM 33.4% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TIAA CREF Investment Management's ACET Position: Q3 2018 in Review

TIAA CREF Investment Management sold out of Adicet Bio (ACET) in Q3 2018, closing a stake of 92 shares — an estimated $94K sold.

TIAA CREF Investment Management first reported a position in ACET in Q1 2018 and held it in 2 quarters. The position peaked at $143K in Q1 2018. 40 funds tracked by Wall St. Rank hold ACET as of Q3 2018.

  • TIAA CREF Investment Management reported no remaining Adicet Bio position as of Q3 2018 after selling out during the quarter.
  • TIAA CREF Investment Management sold 92 Adicet Bio shares in Q3 2018, an estimated $94K.
  • TIAA CREF Investment Management first reported a position in Adicet Bio in Q1 2018 and held it in 2 quarters.
  • TIAA CREF Investment Management's Adicet Bio position peaked at $143K in Q1 2018.
  • 40 funds tracked by Wall St. Rank held Adicet Bio as of Q3 2018.

Based on TIAA CREF Investment Management's 13F filing for Q3 2018, filed 14 Nov 2018.